• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Organisation › Details

Boehringer Ingelheim (Group)

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 143 affiliates in 47 countries and almost 37,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2005, Boehringer Ingelheim posted net sales of 9.5 billion euro while spending almost one fifth of net sales in its largest business segment Prescription Medicines on research and development. *

 

	Start	1885-01-01 established
	Industry	pharmaceutical
	Person	Boehringer, Christian (Boehringer 201207 Chairman of Shareholders’ Committee)
	Person 2	Barner, Andreas (Boehringer)
	Region	Ingelheim
	Country	Germany
	Street	173 Binger Str.
	City	55216 Ingelheim
	Tel	+49-6132-770
		Address record changed: 2018-07-24
Basic data	Employees	I: 50,001 to 100,0 (2016-12-31)
	Currency	EUR
	Annual sales	17,498,000,000 (sales, net, consolidated (2018) 2018-12-31)
	Profit	2,075,000,000 (2018-12-31)
	Cash	4,303,000,000 (2018-12-31)
		* Document for �About Section�:
		Record changed: 2019-09-10

Advertisement

More documents for Boehringer Ingelheim (Group)

• [1] Boehringer Ingelheim. (9/4/19). "Press Release: Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage MEK Inhibitor Compound". Ingelheim & Mumbai....
• [2] Boehringer Ingelheim. (9/3/19). "Press Release: Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/Glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes". Ingelheim & Copenhagen....
• [3] Boehringer Ingelheim. (8/12/19). "Press Release: Boehringer Ingelheim and MD Anderson Form Unique Virtual Research and Development Center to Rapidly Advance New Cancer Therapies". Ingelheim....
• [4] Boehringer Ingelheim. (8/12/19). "Press Release: Boehringer Ingelheim Opens Health Management Centre in China". Shanghai....
• [5] Boehringer Ingelheim. (7/18/19). "Press Release: Boehringer Ingelheim Expands Idiopathic Pulmonary Fibrosis (IPF) Pipeline Through Collaboration and License Agreement with Bridge Biotherapeutics". Ingelheim & Seongnam....
• [6] Boehringer Ingelheim. (7/18/19). "Press Release: INMARK Results Suggest Prompt Treatment of IPF with Antifibrotics to Slow Disease Progression". Ingelheim....
• [7] Boehringer Ingelheim. (7/15/19). "Press Release: Boehringer Ingelheim Acquires Amal Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform". Ingelheim & Geneva....
• [8] Boehringer Ingelheim. (7/1/19). "Press Release: Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis (NASH) R&D Pipeline with New First-in-Class Compound from Yuhan Corporation". Ingelheim & Seoul....
• [9] Boehringer Ingelheim. (6/11/19). "Press Release: The Healthcare of Tomorrow – Boehringer Ingelheim Relies on Digital Transformation". Ingelheim....
• [10] Amal Therapeutics S.A.. (5/2/19). "Press Release: Amal Therapeutics Enters Clinical Collaboration with Boehringer Ingelheim to Evaluate ATP128 in Combination with BI754091". Geneva....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2019. Made in Germany.